SCHEMBL2029705

SCHEMBL2029705

COc1cc(COCc2ccccc2)ccc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.48
HTT P42858 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTR1A P08908 1/20 0.46
ADRA1D P25100 1/20 0.46
ADRA1A P35348 1/20 0.46
ADRA1B P35368 1/20 0.46
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ABCB1 P08183 1/20 0.44
TSHR P16473 1/20 0.43
SIRT6 Q8N6T7 1/20 0.43
CHEK1 O14757 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30963232 1.00 ALDH1A1 (0.53) ALDH1A1TDP1L3MBTL1HTTMEN1
SCHEMBL27390549 0.93 ALDH1A1 (0.51) ALDH1A1TDP1L3MBTL1HTTMAPT
SCHEMBL27856352 0.85 ALDH1A1 (0.56) ALDH1A1TDP1L3MBTL1HTTMAPT
SCHEMBL2031473 0.83 ALDH1A1 (0.51) ALDH1A1TDP1L3MBTL1HTTMAPT
SCHEMBL31224728 0.82 L3MBTL1 (0.49) ALDH1A1L3MBTL1MEN1KMT2AMAPT
SCHEMBL2033918 0.82 KDM4E (0.53) ALDH1A1TDP1L3MBTL1HTTMEN1
SCHEMBL4326387 0.82 KMT2A (0.57) ALDH1A1TDP1L3MBTL1MEN1KMT2A
SCHEMBL9348632 0.82 ALDH1A1 (0.53) ALDH1A1TDP1L3MBTL1HTTMEN1
SCHEMBL2031956 0.81 KDM4E (0.56) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL4461947 0.80 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379510-B1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS ICOS CORP (US) 2011-06-01 EP disclosed
US-20100105683-A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 KEEGAN KATHLEEN S 2010-04-29 US disclosed
US-7608618-B2 Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 ICOS CORPORATION (US) 2009-10-27 US disclosed
US-7067506-B2 Compounds useful for inhibiting Chk1 ICOS CORPORATION (US) 2006-06-27 US disclosed
US-20050245525-A1 Compounds useful for inhibiting CHK1 ICOS CORPORATION (US) 2005-11-03 US disclosed
EP-1379510-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2004-01-14 EP disclosed
US-20030069284-A1 Compounds useful for inhibiting Chk1 ICOS CORPORATION (A WASHINGTON CORPORATION) 2003-04-10 US disclosed
WO-2002070494-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105683-A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 CHEK1, PCNA, CHEK2 ALDH1A1 3047/4885TDP1 221/4885L3MBTL1 310/4885
US-20050245525-A1 Compounds useful for inhibiting CHK1 CHEK1, PCNA, CHEK2 ALDH1A1 3047/4885TDP1 221/4885L3MBTL1 310/4885
US-20030069284-A1 Compounds useful for inhibiting Chk1 CHEK1, PCNA, CHEK2 ALDH1A1 3047/4885TDP1 221/4885L3MBTL1 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.